baber/WOPTO huggingface dataset:
Patent NZ-601731-A (NZ)
Title: Prolyl hydroxylase inhibitors and methods for use
Inventor: KAWAMOTO RICHARD MASARU
IPC: C07C237/42
Filed: 2007-06-26
Abstract: 601731 Disclosed are { [5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} -acetic acid derivatives as represented by the general formula, as inhibitors of human protein prolyl hydroxylase for stimulating an angiogenic response for increasing blood flow, oxygen delivery and energy utilization in ischemic tissues; wherein the specific compounds of formula (I) are chosen from { [5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acid methyl ester, [(3-hydroxy-5-(4-methylphenyl)pyridine-2-carbonyl)amino]acetic acid, { [5-(2-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acid methyl ester, { [5-(4-cyanophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acid, { [5-(4-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acid, { [5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acid, { [5-(2-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acid and 5-(3-chlorophenyl)-N-(2-methylamino-2-oxoethyl)-3-hydroxylpyridin-2-yl amide; or a pharmaceutically acceptable salt thereof. Further disclosed is a composition comprising one or more compounds as defined above, or a pharmaceutically acceptable salt thereof; and one or more excipients or carriers; for treating a disease selected from diabetic retinopathy, macular degeneration, sickle cell anemia, sarcoid, syphilis, pseudoxanthoma elasticum, Paget’s disease, vein occlusion, artery occlusion, carotid obstructive disease, chronic uveitis/vitritis, mycobacterial infections, Lyme’s disease, systemic lupus erythematosis, retinopathy of prematurity, Eales’ disease, Behcet’s disease, infections causing a retinitis or choroiditis, presumed ocular histoplasmosis, Best’s disease, myopia, optic pits, Stargardt’s disease, pars planitis, chronic retinal detachment, hyperviscosity syndrome, toxoplasmosis, trauma post-laser complications, diseases associated with rubeosis, and proliferative vitroeretinopathy, Crohn’s disease and ulcerative colitis, psoriasis, sarcoidosis, rheumatoid arthritis, hemangiomas, Osler-Weber-Rendu disease, or hereditary hemorrhagic telangiectasia, solid or blood borne tumors, acquired immune deficiency syndrome, skeletal muscle and myocardial ischemia, stroke, coronary artery disease, peripheral vascular disease, and coronary artery disease.
Patent NZ-602622-A (NZ)
Title: Derivatives of 1-amino-2-cyclopropylethylboronic acid
Inventor: FLEMING PAUL E
IPC: C07F5/04
Filed: 2011-03-30
Abstract: Disclosed are ((1R)-2-cyclopropyl-1-{ [(2S)-3-phenyl-2-(amino)propanoyl]amino} ethyl)boronic acid derivatives as represented by the general formula (I), or a pharmaceutically acceptable salt or boronic acid anhydride thereof, wherein: A is 0, 1, or 2; P is hydrogen, Rc-C(O)-, Rc-O-C(O)-, Rc-N(R4c)-C(O)-, Rc-S(O)2-, or Rc-N(R4c)-S(O)2-; Z1 and Z2 are each independently hydroxy, alkoxy, aryloxy, or aralkoxy; or Z1 and Z2 together form a moiety derived from a boronic acid complexing agent; and wherein the remaining substituents are as defined herein. Representative compounds include ((1R)-2-cyclopropyl-1-{ [(2S)-3-phenyl-2-({ [4-(pyridin-2-yloxy)phenyl]sulfonyl} amino)propanoyl]amino} ethyl)boronic acid, ((1R)-2-cyclopropyl-1-{ [(2S)-3-phenyl-2-({ [4-(pyridin-3-yloxy)phenyl]sulfonyl} amino)propanoyl]amino} ethyl)boronic acid, { (1R)-2-cyclopropyl-1-[((2S)-2-{ [(6-morpholin-4-ylpyridin-3-yl)sulfonyl]amino} -3-phenylpropanoyl)amino]ethyl} boronic acid, [(1R)-1-({ (2S)-2-[(1,3-benzothiazol-6-ylsulfonyl)amino]-3-phenylpropanoyl} amino)-2-cyclopropylethyl]boronic acid, ((1R)-2-cyclopropyl-1-{ [(2S)-2-({ [3-(2-methyl-1,3-thiazol-4-yl)phenyl]sulfonyl} amino)-3-phenylpropanoyl]amino} ethyl)boronic acid, { (1R)-2-cyclopropyl-1-[((2S)-2-{ [(1-methyl-1H-indol-4-yl)sulfonyl]amino} -3-phenylpropanoyl)amino]ethyl} boronic acid, [(1R)-2-cyclopropyl-1-({ (2S)-3-phenyl-2-[(pyrazin-2-ylcarbonyl)amino]propanoyl} amino)ethyl]boronic acid, ((1R)-2-cyclopropyl-1-{ [(2S)-3-phenyl-2-({ [4-(pyridin-3-ylsulfonyl)phenyl]sulfonyl} amino)propanoyl]amino} ethyl)boronic acid, ((1R)-1-{ [(2S)-2-({ [4-(1H-benzimidazol-5-yloxy)phenyl]sulfonyl} amino)-3-phenylpropanoyl]amino} -2-cyclopropylethyl)boronic acid and { (1R)-2-cyclopropyl-1-[((2S)-2-{ [(2-phenoxypyrimidin-5-yl)sulfonyl]amino} -3-phenylpropanoyl)amino]ethyl} boronic acid. Also disclosed is a pharmaceutical composition comprising a compound as defined above, and a pharmaceutically acceptable carrier or diluent, for use in treating cancer in a patient in need thereof, and preferably where the cancer is selected from the group consisting of multiple myeloma, mantle cell lymphoma, follicular lymphoma, amyloidosis, head and neck cancer, soft-tissue sarcoma, non-small cell lung cancer, and prostate cancer.
Patent NZ-603137-A (NZ)
Title: N-(hetero)aryl,2-(hetero)aryl-substituted acetamides foruse as wnt signaling modulators
Inventor: CHENG DAI
IPC: A61K31/4402
Filed: 2010-03-01
Abstract: 603137 Disclosed herein is a compound of the formula (1) or (2), wherein the variable are defined in the specification, and the use thereof in the treatment of a Wnt-mediated disorder, such as keloids, fibrosis, proteinuria, kidney graft rejection, osteoarthritis, Parkinson's disease, cystoid macular edema, retinopathy, macular degeneration or a cell proliferative disorder associated with aberrant Wnt signalling activity. Exemplary compounds include: N-(6-methoxybenzo[d]thiazol-2-yl)-2-(3-(pyridin-4-yl)phenyl)acetamide; 2-(3-(2-methylpyridin-4-yl)phenyl)-N-(6-phenylpyridin-3-yl)acetamide; 2-(3-(2-methylpyridin-4-yl)phenyl)-N-(6-(pyrazin-2-yl)pyridin-3-yl)acetamide; and 2',3-dimethyl-5-(2-oxo-2-(5-(pyrazin-2-yl)pyridin-2-ylamino )ethy1)-2,4'-bipyridine l'-oxide.
Patent NZ-603726-A (NZ)
Title: Flexible post
Inventor: HERDMAN JEFFREY STEWART
IPC: E01F9/627
Filed: 2011-05-19
Abstract: 603726 A flexible post for use in a wire cable safety barrier, said flexible post being substantially elastically deformable and including a laminate formed by bonding together under heat and pressure an assembly of layers including at least one layer comprising uncured wire reinforced elastomer material, said post including one or more apertures for retaining therein a respective wire cable of the wire cable safety barrier.
Patent NZ-612228-A (NZ)
Title: Producing edible residues from ethanol production
Inventor: MEDOFF MARSHALL
IPC: A23K10/38
Filed: 2010-10-12
Abstract: Disclosed is a method comprising irradiating edible residues, the method comprising: irradiating, with electron beam radiation, edible residues that have been produced as a by-product of an ethanol manufacturing process, wherein the edible residues comprise 5 lignin, xylose and minerals, wherein the edible residues contain an antibiotic, and irradiating is performed under conditions selected to inactivate or destroy the antibiotic.
Patent NZ-612380-A (NZ)
Title: Modulators of toll-like receptors
Inventor: ROETHLE PAUL A
IPC: C07D295/04
Filed: 2009-12-07
Abstract: The disclosure provides intermediates ion the preparation of modulators of toll-like receptors. Such compounds may be converted to the modulators by reactions given in the specification.
Patent NZ-614053-A (NZ)
Title: Portable dialysis machine
Inventor: FULKERSON BARRY NEIL
IPC: B01D61/28
Filed: 2011-09-25
Abstract: The specification discloses a portable dialysis machine having a detachable controller unit and base unit. The controller unit includes a door having an interior face, a housing with a panel, where the housing and panel define a recessed region configured to receive the interior face of the door, and a manifold receiver fixedly attached to the panel. The base unit has a planar surface for receiving a container of fluid, a scale integrated with the planar surface, a heater in thermal communication with the planar surface, and a sodium sensor in electromagnetic communication with the planar surface. Embodiments of the disclosed portable dialysis system have improved structural and functional features, including improved modularity, ease of use, and safety features.
Patent NZ-616037-A (NZ)
Title: Multilayer heat-shrinkable asymmetrical film
Inventor: FORLONI ROBERTO
IPC: C08L77/02
Filed: 2012-03-21
Abstract: Disclosed is multilayer heat-shrinkable asymmetrical film comprising at least the following layers: an outer sealing layer selected from polyethylene or polypropylene; an inner barrier layer selected from a thermoplastic resin such as ethylene-vinyl acetate copolymers (EVOH); and an outer skin layer comprising of blend of at least one polyamide and at least one polyester wherein the percentage of polyamide in the blend is at least 60%. The heat shrinkable film, used in product packaging of lids, bags, pouches or tubing, have reduced curling and skeleton breakage in the manufacturing process while retaining desirable properties such as gloss and transparency.
Patent NZ-623929-A (NZ)
Title: Use of avermectin derivative for increasing bioavailability and efficacy of macrocylic lactones
Inventor: LESPINE ANNE
IPC: A61P35/00
Filed: 2012-10-18
Abstract: Provided is the use of avermectin derivative compounds of formula I wherein the variables are as defined in the specification, in combination with an active agent which is an antiparasitic agent, an antitumoral agent, an antiviral agent, an anti-epileptic agent, an antibacterial agent or an antifungal agent, such as another macrocyclic lactone. The avermectin derivative compounds may improve the efficacy of the active agent by inhibiting membrane-bound transporter proteins that transport exogenous compounds out of target cells.
Patent NZ-624019-A (NZ)
Title: Method for inhibition of deubiquitinating activity
Inventor: LINDER STIG
IPC: C07D223/08
Filed: 2012-10-15
Abstract: Disclosed herein are compounds of the formula S-1 where the substituents are as defined herein. Examples of the compounds include (3E, 5E)‐3,5‐Bis(phenylmethylidene)azepan‐4‐one and (3E,5E)‐5‐[(4‐chlorophenyl)methylidene]‐3‐[(4‐nitrophenyl)methylidene]azepan‐4‐one. The compounds are capable of abrogating the deubiquitinating (DUB) activity of the 19S RP DUBs and are therefore suitable for treating cancer, in particular of cancer refractory to treatment by chemotherapy using compounds such as bortezomib. Also disclosed are corresponding methods of treatment and pharmaceutical compositions comprising the compounds.
Patent NZ-624123-A (NZ)
Title: Boronate ester compounds and pharmaceutical compositions thereof
Inventor: ELLIOTT ERIC L
IPC: C07F5/06
Filed: 2009-06-16
Abstract: Disclosed are processes for preparing peptide boron esters of formula (II) where the substituents are as disclosed in the description. Example of the process is the preparing of 2,2’-{ 2-[(1R)-1-({ [(2,5-dichlorobenzoyl)amino]acetyl} amino)-3-methylbutyl]-5-oxo-1,3,2-dioxaborolane-4,4-diyl} diacetic acid, the process comprising reacting an intermediate consisting of a boronate ester trimer, with citric acid. The compounds of formula (II) are useful in treating cancer.
Patent NZ-626585-A (NZ)
Title: Compact oronasal patient interface
Inventor: KWOK PHILIP RODNEY
IPC: A61M16/06
Filed: 2004-12-24
Abstract: A respiratory mask has nasal nozzles and a mouth covering to deliver gas to a patient.
Patent NZ-629404-A (NZ)
Title: Improved connector
Inventor: HANLEY RONALD CHARLES
IPC: F16B21/18
Filed: 2014-08-26
Abstract: A panel type snap connector for fastening in fire rated conditions has metal base containing resilient (typically plastic) interface in turn containing metal clip to removably retain end of male connector. A kit of parts and details of the resilient interface are also disclosed.
Patent NZ-701038-A (NZ)
Title: Treating acute decompensated heart failure with relaxin
Inventor: WHITEHOUSE MARTHA JO
IPC: C07K14/64
Filed: 2009-05-15
Abstract: Disclosed is the use of a therapeutically effective amount of a pharmaceutically active H2 relaxin in the manufacture of a medicament for reducing worsening heart failure in a hypertensive or normotensive human subject with acute heart failure.
Patent NZ-704531-A (NZ)
Title: Process for producing wind power plant rotor blades and for producing a mould core therefor
Inventor: KAMKE INGO
IPC: B32B38/18
Filed: 2013-07-25
Abstract: The invention concerns a process for the production of a mould core for the one-part production of wind power installation rotor blades. According to the invention the method includes the steps: providing a flexible hollow body, for example a film tube, inserting the hollow body between at least two mould portions which are so arranged relative to each other that they form a negative shape of the rotor blade to be produced, filling the hollow body with loose material prior to or after insertion of the hollow body between the mould portions, and producing a reduced pressure in the hollow body after it has been filled and inserted in such a way that the hollow body solidifies. The invention further concerns a process for producing a reduced pressure between mould portions and mould core.
Patent NZ-705641-A (NZ)
Title: Maleate salts of (e)-n-{ 4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl} -4-(dimethylamino)-2-butenamide and crystalline forms thereof
Inventor: LU QINGHONG
IPC: C07D401/12
Filed: 2008-10-16
Abstract: Disclosed herein are maleate salt forms of (E)-N-{ 4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl} -4-(dimethylamino)-2-butenamide, (NERATINIB) methods of preparing crystalline maleate salt forms such as a partially hydrate form, the associated compounds, such as its degradation and impurities and pharmaceutical compositions containing the same. The maleate salts are useful in treating cancers, particularly those affected by kinases of the epidermal growth factor receptor family.
Patent NZ-708878-A (NZ)
Title: Herbicidal compositions comprising 4-amino-3-chloro-6-(4-chloro-2-fluoro-3-methoxyphenyl) pyridine-2-carboxylic acid or a derivative thereof and flurtamone
Inventor: SATCHIVI NORBERT
IPC: C07D213/79
Filed: 2013-12-19
Abstract: Provided herein are herbicidal compositions and methods employing combinations of (a) a compound of formula (I): or an agriculturally acceptable salt or ester thereof and (b) flurtamone. In certain embodiments the combinations include flufenacet or diflufenican as a third herbicidally active component.
Patent NZ-711326-A (NZ)
Title: A process for sodium salt of (2s, 5r)-2-carboxamido-7-oxo-6-sulfooxy -1,6-diaza-bicyclo[3.2.1]octane
Inventor: PATEL MAHESH VITHALBHAI
IPC: C07D471/08
Filed: 2013-10-12
Abstract: A process for preparation of a sodium salt of (2S, 5R)-2-carboxamido-7-oxo-6-sulfooxy-1,6-diaza-bicyclo[3.2.1]octane having Formula (I) is disclosed.
Patent NZ-712141-A (NZ)
Title: Neuroactive steroids and methods of use thereof
Inventor: SALITURO FRANCESCO
IPC: C07J9/00
Filed: 2014-03-13
Abstract: (3alpha, 3beta)-disubstituted 17beta steroidal compounds of formula (I), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, are provided for the prevention and treatment of a variety of CNS-related conditions.
Patent NZ-715683-A (NZ)
Title: Use of 2-amino-2-ethyl-1,3-propanediol as additive in aqueous suspensions of calcium carbonate-comprising materials while maintaining stable suspension conductivity
Inventor: GANE PATRICK A C
IPC: C09C1/02
Filed: 2014-07-07
Abstract: Use of 2-amino-2-ethyl-1,3-propanediol as an additive in an aqueous suspension, containing from 25 to 62 vol. % of at least one calcium carbonate-comprising material, wherein the use provides improved stability with regard to the conductivity of the suspension.
Patent NZ-716089-A (NZ)
Title: Tobacco pouch
Inventor: SÜSS DANIEL
IPC: B65D33/25
Filed: 2014-08-12
Abstract: Disclosed is a tobacco pouch that seeks to store separately various quantities of tobacco using a minimal amount of packaging, has a conventional format, and is easier for the user to handle the tobacco pouch and the tobacco prior to creating individual cigarettes. The tobacco pouch has a front panel and a back panel, which are connected with one another via a first folding line at a first lateral edge, via a first connecting means at a second lateral edge, and via a second connecting means at a lower edge, a strip-shaped, openable first closure running along an upper edge from the first folding line to the first connecting means, sealing an opening, and at least one strip-shaped, openable second closure located in between the first closure and the second connecting means and running from the first folding line up to the first connecting means, dividing the inside of the tobacco pouch into at least two chambers.
Patent NZ-734446-A (NZ)
Title: Pharmaceutical formulations of bruton’s tyrosine kinase inhibtor
Inventor: KUEHL ROBERT
IPC: A61K31/436
Filed: 2016-03-02
Abstract: Described herein are pharmaceutical formulations of Bruton’s tyrosine kinase (Btk) inhibitor 1- ((R)-3-(4-amino-3-(4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l-yl)piperidin-l-yl)prop-2- en-l-one. Also disclosed are methods of using the Btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
Patent NZ-749136-A (NZ)
Title: Methods of immunotherapy
Inventor: KHANNA RAJIV
IPC: G01N33/50
Filed: 2017-05-25
Abstract: Provided herein are methods and compositions related to the selection T cells and/or subjects for adoptive immunotherapy of multiple sclerosis based on the expression of one or more biomarkers selected from IFNg, CD107a, IL-2, and TNF
Patent NZ-751227-A (NZ)
Title: Tofacitinib oral sustained release dosage forms
Inventor: HERBIG SCOTT MAX
IPC: A61K9/20
Filed: 2014-03-12
Abstract: The present invention relates to oral sustained release formulations of tofacitinib and pharmaceutical acceptable salts thereof. The formulations described herein have desirable pharmacokinetic characteristics.
Patent PT-104489-A (PT)
Title: Central hidroeléctrica equipada com estação elevatória automática
Inventor: ROQUE FRANCISCO FERNANDES PEREIRA
IPC: E02B9/00
Filed: 2009-04-06
Abstract: A ESTAÇÃO ELEVATÓRIA AUTOMÁTICA É CONSTITUÍDA POR: UM PAR DE ECLUSAS GÉMEAS, MAS SE FOR NECESSÁRIO PODE CONSTRUIR-SE MAIS ECLUSAS NO MESMO NÍVEL. EM CADA ECLUSA SOBE E DESCE UMA PLATAFORMA FLUTUANTE (2), QUE FAZ SUBIR E DESCER OS ENORMES ÊMBOLOS (4) DAS BOMBAS (5). A ÁGUA (1) PRESSIONADA PELOS ÊMBOLOS (4) DAS BOMBAS (5) É ENCAMINHADA PARA A CONDUTA DE SAÍDA (8) ATRAVÉS DA VÁLVULA (6) DE LIGAÇÃO. QUANDO A ECLUSA COMEÇA A DESCARREGAR, A PLATAFORMA FLUTUANTE (2) COMEÇA A DESCER, PUXANDO OS ENORMES ÊMBOLOS (4) PARA BAIXO, FAZENDO COM QUE A ÁGUA QUE SE ENCONTRA NA CONDUTA DE ENTRADA (7), ATRAVÉS DA VÁLVULA (6) DE LIGAÇÃO ENTRE NA ECLUSA, RECOMEÇANDO UM NOVO CICLO. DEVIDO À ENORME FORÇA QUE AS PLATAFORMAS FLUTUANTES (2) TÊM DEBAIXO PARA CIMA, (QUANDO ESTÃO A SUBIR NAS RESPECTIVAS ECLUSAS), E TAMBÉM DEVIDO ÀS GRANDES DIMENSÕES DAS BOMBAS (5), UM CONJUNTO DE DUAS OU MAIS ESTACÕES ELEVATÓRIAS AUTOMÁTICAS, PODE DEVOLVER MAIS DE 70% DA ÁGUA A BARRAGEM.
Patent PT-104702-A (PT)
Title: Formulações aquosas de revestimento para aplicação no tratamento superficial de substratos celulósicos
Inventor: NETO CARLOS PASCOAL
IPC: C09D101/02
Filed: 2009-07-31
Abstract: A PRESENTE INVENÇÃO REFERE-SE À APLICAÇÃO DE NOVAS FORMULAÇÕES DE REVESTIMENTO, CONTENDO QUITOSANO (E SEUS DERIVADOS) E CELULOSE BACTERIANA, PARA O MELHORAMENTO DAS PROPRIEDADES FINAIS DE MATERIAIS DE BASE CELULÓSICA, COMO POR EXEMPLO PAPÉIS E MATERIAIS TÊXTEIS. O PROCESSO ENVOLVE A PREPARAÇÃO DE MISTURAS HOMOGÉNEAS DE CELULOSE BACTERIANA E QUITOSANO E O TRATAMENTO SUPERFICIAL DOS SUBSTRATOS CELULÓSICOS COM ESTAS MISTURAS. OS TRATAMENTOS SUPERFICIAIS DESCRITOS MELHORAM SUBSTANCIALMENTE AS PROPRIEDADES DE SUPERFÍCIE, MECÂNICAS, ÓPTICAS, DE BARREIRA, ANTIMICROBIANAS E A APTIDÃO À IMPRESSÃO DOS SUBSTRATOS CELULÓSICOS.
Patent PT-105420-A (PT)
Title: Aplicação de leveduras vínicas imobilizadas em camada dupla de alginato-quitosano para remoção da acidez volátil em mostos e vinhos
Inventor: CORREIA VILELA MOURA ALICE MARIA
IPC: C12G1/10
Filed: 2010-12-09
Abstract: PROCESSO DE REMOÇÃO DA ACIDEZ VOLÁTIL DE MOSTOS E VINHOS CARACTERIZADO POR COLOCAR EM CONTACTO A AMOSTRA DE MOSTOS/VINHOS A TRATAR COM LEVEDURA VÍNICAS SACCHAROMYCES CEREVISIAE - IMOBILIZADAS NUMA MATRIZ DE DUPLA CAMADA DE ALGINATO-QUITOSANO. AS ESTIRPES DE SACCHAROMYCES CEREVISIAE, PODEM SER UTILIZADAS NA FORMA LIVRE OU IMOBILIZADAS EM ESFERAS DE DUPLA CAMADA DE ALGINATO-QUITOSANO.
Patent RO-82809-A (RO)
Inventor: BOWERS JOHN E
IPC: C22B13/06
Filed: 1981-06-18
Abstract: A continuous method and apparatus for removing copper from lead comprises introducing molten lead and sulphur to the upper end of a vertical stirred reaction vessel, maintaining a dispersion of sulphur in the lead without substantial back-mixing and thereafter recovering the dispersion and allowing the formed copper sulphide to float to the surface. The process is suitable for continuous operation on a small scale, e.g. 3 tons per hour, is environmentally acceptable and requires a lead inventory only about one third of that required by conventional batch processes.
Patent RU-94007884-A (RU)
Inventor: OGULOV A T
IPC: A61H39/04
Filed: 1994-01-10
Abstract: FIELD: medicine. SUBSTANCE: method involves pressing tegmental tissues in zone of internal organ projection until pain feeling arises. Pressure force is fixed at the level of pain threshold and kept until the pain feeling vanishes. Then the place and angle of applying pressure are changed and the procedure is repeated scanning the whole zone of the internal organ projection. EFFECT: enhanced effectiveness of treatment.
Patent RU-94016271-A (RU)
Inventor: FARBER B S
IPC: B60Q9/00
Filed: 1994-04-24
Abstract: FIELD: transport; vehicle carried control systems. SUBSTANCE: controlled parameter sensor are connected with one of outputs of gating circuits and OR gate. Second output of gating circuits is connected through voltage decoder with first clock pulse generator. Inputs of gating circuits are connected with input of decoder. Output of decoder is connected with one of inputs of switches. Other inputs of switches are connected through frequency dividers with second clock pulse generator. Outputs of switches are connected with one of inputs of gating circuits second input of which is connected with OR gate, and outputs are connected with input of amplifiers whose outputs are connected with signalling device in form of vibrators. EFFECT: enlarged operating capabilities, enhanced reliability of system operation. 1 cl, 2 dwg